Targeted Synthetic DMARDs Medication Table PDF
Document Details
Uploaded by DignifiedRadon
Royal Holloway, University of London
2023
Tags
Summary
This document presents a medication information table about Targeted Synthetic DMARDs, specifically tofacitinib. It outlines key aspects such as therapeutic uses, potential adverse reactions, and client instructions. The resource, provided by Assessment Technologies Institute, also details contraindications and drug interactions.
Full Transcript
Pharmacology Made Easy Medication Information Table Targeted Synthetic DMARDs – tofacitinib Category Information THERAPEUTIC USE Decrease joint inflammation and subs...
Pharmacology Made Easy Medication Information Table Targeted Synthetic DMARDs – tofacitinib Category Information THERAPEUTIC USE Decrease joint inflammation and subsequently joint damage. ADVERSE DRUG Neutropenia REACTIONS Increased risk for upper respiratory tract infection, urinary tract infection, and more serious infections (tuberculosis, pneumonia, cellulitis, herpes zoster) Elevated liver enzymes, serum creatinine, and lipids Gastrointestinal perforation INTERVENTIONS Monitor CBC, liver enzymes, and lipid profile. Monitor for manifestations of infection. Monitor for abdominal pain. ADMINISTRATION Give tablet or oral solution once daily (twice daily if extended release tablet. Extended release tablet must be swallowed whole and not chewed, crushed, or split. CLIENT INSTRUCTIONS Report chest pain or dyspnea. Report manifestations of infection. Report edema, discoloration, tenderness, or swelling in the extremities. Keep immunizations up to date; avoid live vaccines. Avoid breastfeeding while on this medication. CONTRAINDICATIONS Anemia, neutropenia, leukopenia Active infection or history of serious infection, such as tuberculosis PRECAUTIONS Clients who have increased risk for gastrointestinal perforation Clients who have a history of malignancy INTERACTIONS Concurrent use of other medications that have immunosuppressive effects (biologic DMARD, cyclosporine, corticosteroids) may increase immunosuppressive effects of targeted synthetic DMARD. Use of ketoconazole, fluconazole, rifampin, and other anti-infectives should be avoided, or should have dosages adjusted to prevent additive or inhibiting effects of the anti-infective. Copyright ©2023 Assessment Technologies Institute, L.L.C. All rights reserved. This resource is copyright protected material of ATI and is provided for use solely under license by ATI. Copying, distributing, or posting this material on the internet or social media is strictly prohibited. Posting on institution LMS requires ATI’s prior written permission. PAGE 1 www.atitesting.com ©2023 Assessment Technologies Institute, L.L.C.
